▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BIIB

BIIB — BIOGEN INC.

—
Nasdaq · Health Care · Biotechnology · CIK 875045 ·
Last close
$200.05
Market Cap
$29.53B
52W High
$205.97
52W Low
$168.64
ADV30
1,053,350
Next earnings
2026-07-30
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,477,800,000 1,816,800,000 459,800,000 319,500,000 29,483,100,000 3,382,700,000 10,831,400,000
Dec 2025 2,279,400,000 1,783,900,000 385,500,000 -48,900,000 29,439,500,000 3,008,500,000 11,182,700,000
Sep 2025 2,534,700,000 1,860,300,000 606,500,000 466,500,000 29,207,500,000 3,862,800,000 11,000,000,000
Jun 2025 2,645,500,000 2,040,500,000 851,800,000 634,800,000 28,330,200,000 2,758,800,000 10,696,200,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,590,800,000
Investing CF
$-1,533,300,000
Financing CF
$-322,700,000
CapEx
$-274,500,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$9.32
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$20,872,200,000
Inventory
$1,949,000,000
Receivables
$1,790,400,000
ST Investments
$900,000,000
EBIT TTM
$1,898,100,000
Pretax Income TTM
$1,623,000,000
Interest Exp TTM
$275,100,000
Analysts
29

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,937,399,808
EBITDA
$3,539,599,872
Free Cash Flow
$1,930,925,056
Enterprise Value
$31,814,004,736
Total Cash
$4,282,700,032
Total Debt
$6,561,900,032
Shares Out
147,637,117
Trailing EPS
$9.30
Book Value
$126.37
ROE
7.7%
ROA
6.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,890,600,000 2,469,000,000 1,292,900,000 29,439,500,000 11,182,700,000 — 2,204,600,000
Dec 2024 9,675,900,000 2,280,400,000 1,632,200,000 28,049,300,000 11,333,300,000 — 2,875,500,000
Dec 2023 9,835,600,000 1,847,700,000 1,161,100,000 26,844,800,000 12,045,400,000 — 1,547,200,000
Dec 2022 10,173,400,000 2,901,900,000 3,046,900,000 24,554,100,000 11,165,700,000 — 1,384,300,000

TTM Snapshot

Revenues TTM
$10,283,500,000
NetIncome TTM
$1,784,300,000
OpCashFlow TTM
$0
Assets (Latest)
$28,049,300,000
Forward EPS
$16.68

Max Pain — expiry 2026-06-18

max pain strike: $180.00 · spot: $197.94 · call oi: 6,513 · put oi: 4,635
Expected Move to 2026-06-18: ±$5.42 (2.74%) — implied range $192.52 – $203.37 · ATM straddle on $197.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RVMD Revolution Medicines, Inc. $32.71B $153.87 —
BNTX BioNTech SE $22.90B $90.54 —
MRNA Moderna, Inc. $19.80B $49.91 —
NBIX NEUROCRINE BIOSCIENCES INC $16.06B $159.76 —
ARGX ARGENX SE $55.57B $893.52 —

News headlines (Yahoo Finance, 1h cache)

3 Overrated Stocks Walking a Fine Line
2026-06-15 11:32 · Yahoo
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
2026-06-11 10:20 · Yahoo
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
2026-06-10 12:33 · Yahoo
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
2026-06-10 11:06 · Yahoo
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton
2026-06-09 12:16 · Yahoo
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?
2026-06-05 20:04 · Yahoo
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data
2026-06-05 19:12 · Yahoo
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
2026-06-05 16:04 · Yahoo
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
2026-06-04 15:30 · Yahoo
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
2026-06-04 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →